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BACKGROUND: Identification of people with hypertrophic 
cardiomyopathy (HCM) who are at risk of sudden cardiac death (SCD) 
and require a prophylactic implantable cardioverter defibrillator is 
challenging. In 2014, the European Society of Cardiology proposed a 
new risk stratification method based on a risk prediction model (HCM 
Risk-SCD) that estimates the 5-year risk of SCD. The aim was to externally 
validate the 2014 European Society of Cardiology recommendations in a 
geographically diverse cohort of patients recruited from the United States, 
Europe, the Middle East, and Asia.
METHODS: This was an observational, retrospective, longitudinal  
cohort study.
RESULTS: The cohort consisted of 3703 patients. Seventy three (2%) 
patients reached the SCD end point within 5 years of follow-up (5-year 
incidence, 2.4% [95% confidence interval {CI}, 1.9–3.0]). The validation 
study revealed a calibration slope of 1.02 (95% CI, 0.93–1.12), C-index 
of 0.70 (95% CI, 0.68–0.72), and D-statistic of 1.17 (95% CI, 1.05–1.29). 
In a complete case analysis (n= 2147; 44 SCD end points at 5 years), 
patients with a predicted 5-year risk of <4% (n=1524; 71%) had an 
observed 5-year SCD incidence of 1.4% (95% CI, 0.8–2.2); patients with 
a predicted risk of ≥6% (n=297; 14%) had an observed SCD incidence of 
8.9% (95% CI, 5.96–13.1) at 5 years. For every 13 (297/23) implantable 
cardioverter defibrillator implantations in patients with an estimated 
5-year SCD risk ≥6%, 1 patient can potentially be saved from SCD.
CONCLUSIONS: This study confirms that the HCM Risk-SCD model 
provides accurate prognostic information that can be used to target 
implantable cardioverter defibrillator therapy in patients at the highest 
risk of SCD.
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Hypertrophic cardiomyopathy (HCM) causes sud-den cardiac death (SCD) in young and otherwise well individuals.1,2 Prophylactic treatment with 
implantable cardioverter defibrillators (ICDs) is the cur-
rent standard of care for people with HCM deemed 
to be at high risk of SCD, but the identification of in-
dividuals most likely to benefit from device implanta-
tion is challenging.1,2 In 2014, the European Society of 
Cardiology (ESC) proposed a new approach to risk pre-
diction that uses a clinical risk tool (HCM Risk-SCD) to 
estimate a 5-year risk of SCD. Although internally vali-
dated in a large multicenter cohort,3 articles published 
since the ESC recommendations have been inconsistent 
with respect to the performance of the ESC guidelines 
in different populations.4–7 The aim of this study was 
to validate the 2014 ESC recommendations in a large, 
geographically diverse cohort recruited from centers in 
the United States, Europe, the Middle East, and Asia.
METHODS
Study Design
This international EVIDENCE-HCM study (External Validation 
Study of the 2014 European Society of Cardiology Guideline 
on Sudden Cardiac Death Prevention in Hypertrophic 
Cardiomyopathy) used a retrospective, multicenter, longitudi-
nal cohort of patients. The HCM Risk-SCD model was statisti-
cally validated and the clinical impact of the 2014 ESC SCD 
risk stratification guidelines examined using SCD end points 
within 5 years of baseline clinical evaluation.
The study conforms to the principles of the Declaration 
of Helsinki. The sponsors of this study did not have a role 
in study design, data collection, analysis, or interpretation. 
Drs O’Mahony, Omar, Jichi, and Elliott had access to all data 
and final responsibility for submission of the manuscript. The 
authors from each participating center guarantee the integ-
rity of data from their institution and had approval from a 
local ethics committee/internal review board. Subjects gave 
informed consent in accordance to local protocol. All inves-
tigators have agreed to the manuscript as written. The data, 
analytic methods, and study materials will not be made avail-
able to other researchers for purposes of reproducing the 
results or replicating the procedure.
Study Population
The study cohort consisted of consecutively evaluated patients 
with HCM at 14 participating centers in the United States, 
Europe, the Middle East, and Asia (Table I in the online-only 
Data Supplement). Included patients were evaluated between 
1970 and 2014 (most patients [69%] were evaluated from 
2000 onward; Figure I in the online-only Data Supplement). 
None of the patients were included in the original HCM Risk-
SCD development study.3 Only adult patients (≥16 years of 
age) without prior ventricular fibrillation or sustained ventric-
ular tachycardia were studied.
HCM was defined as a maximum left ventricular wall 
thickness (MWT) ≥15 mm unexplained by abnormal loading 
conditions8 or in accordance with published criteria for the 
diagnosis of disease in relatives of patients with unequivocal 
disease.9 Patients known to have metabolic diseases or syn-
dromic causes of HCM were excluded.
Patient Assessment and Data Collection
Patients underwent clinical assessment, pedigree analysis, physi-
cal examination, ECG (resting and ambulatory), and transtho-
racic echocardiography. Data were collected independently at 
each participating center using the same methodology.
Predictor Variables and Calculation of 
5-Year Risk of SCD
The following predictor variables were recorded at the time of 
first evaluation at each participating center:
1. Age at time of evaluation (years)
2. Family history of SCD in ≥1 first-degree relatives <40 
years of age or SCD in a first-degree relative with con-
firmed HCM (post- or antemortem diagnosis) at any 
age
3. MWT in the parasternal short- and long-axis plane using 
2-dimensional echocardiography (mm)
4. Left atrial diameter by M-Mode or 2-dimensional echo-
cardiography in the parasternal long-axis plane (mm)
5. Maximal instantaneous left ventricular outflow tract 
gradient (LVOTgmax) at rest and with Valsalva provo-
cation (irrespective of concurrent medical treatment) 
using continuous-wave Doppler echocardiography 
(mm Hg)
6. Nonsustained ventricular tachycardia defined as ≥3 
consecutive ventricular beats at a rate of ≥120 beats 
per minute and <30 s in duration on Holter monitor-
ing (minimum duration 24 hours) at or before first 
evaluation
Clinical Perspective
What Is New?
• This is a large, international, multicenter study 
designed to validate the 2014 European Society of 
Cardiology guidelines on sudden cardiac death pre-
vention in hypertrophic cardiomyopathy.
• The guidelines discriminate high- from low-risk 
patients reasonably well.
• There is a good agreement between predicted risk 
and subsequent events.
What Are the Clinical Implications?
• Patients with a 5-year sudden cardiac death risk 
≥6% should be offered an implantable cardioverter 
defibrillator.
• Patients with a 5-year sudden cardiac death risk 
≤4% should be regularly reassessed.
• In intermediate-risk patients (5-year risk of >4% 
to <6%), an implantable cardioverter defibrillator 
may be considered following an appraisal of the 
lifelong risks and benefits of device therapy.
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7. Unexplained syncope at or before first evaluation
The 5-year risk of SCD was calculated using the following 
equation3:
ˆ exp )PSCD at years
PI
5 1= −
(0.998
where PI is the prognostic index = 0.15939858×MWT 
– 0.00294271×MWT2 + 0.0259082×left atrial diameter 
+ 0.00446131×LVOTgmax + 0.4583082×family history of 
SCD + 0.82639195×nonsustained ventricular tachycardia + 
0.71650361×unexplained syncope – 0.01799934×age.
In keeping with clinical practice and the 2014 ESC rec-
ommendations,10 patients with extreme clinical characteristics 
who were underrepresented in the published development 
cohort were not used for validation but are reported sepa-
rately. The extreme clinical characteristics were defined a 
priori as left atrial diameter >67 mm, LVOTgmax >154 mm Hg, 
MWT >35 mm, or age >80 years. Such patients formed ≤1% 
of the original development cohort.3
Study End Point
The study end point was SCD or an equivalent event. SCD 
was defined as witnessed sudden death with or without 
documented ventricular fibrillation or death within 1 hour 
of new symptoms or nocturnal deaths with no antecedent 
history of worsening symptoms.11 Aborted SCD during fol-
low-up and appropriate ICD shock therapy were considered 
equivalent to SCD.12–17 As in previous studies, ICD shocks 
were considered appropriate if the treated tachyarrhyth-
mia was ventricular in origin.12–17 The cause of death was 
ascertained by the treating cardiologists at each center by 
using hospital and primary health care records, death certifi-
cates, postmortem reports, and interviews with witnesses. 
Deaths were assessed without knowledge of HCM Risk-SCD 
estimates.
General Statistical Methods
All statistical analyses were performed using STATA (version 
14). Variables are expressed as mean±SD, median (25th, 75th 
percentiles), or counts and percentages as appropriate. The 
follow-up time for each patient was calculated from the date 
of his or her first evaluation to the date of reaching the study 
end point, or death from another cause, or to the date of his 
or her most recent evaluation. The annual event rate was cal-
culated by dividing the number of patients reaching the end 
point by the total follow-up period for that end point. The 
cumulative probability for the occurrence of an outcome was 
estimated using the Kaplan-Meier method.
Missing Data
To determine the degree of bias attributable to missing data, 
the characteristics of patients with missing information were 
compared with those with complete information. Logistic 
regression was used to identify the predictors of missingness. 
Data were assumed to be missing at random, and values for 
the missing predictors were imputed using multiple imputa-
tion techniques based on chained equations.18 All predic-
tors of missingness were included in the multiple imputation 
model, together with the outcome, all prespecified predictors 
of the risk model, and the estimate of the cumulative hazard 
function.19 A total of 45 imputed data sets were generated, 
and the estimates were combined using Rubin rules.20
HCM Risk-SCD Model Validation
The calibration slope was used to assess the degree of agree-
ment between the observed and predicted hazards of SCD.21 
A value close to 1 suggests good overall agreement. Graphical 
comparisons of the observed and predicted SCD at 5 years by 
risk groups (group cutoffs: 0%–2%, 2%–4%, 4%–6%, and 
>6% 5-year risk of SCD) were performed. The C-index as pro-
posed by Uno and the D-statistic were used to measure how 
well the model discriminated between patients with high and 
low risk of SCD.22,23 A value of 0.5 for the C-index indicates 
no discrimination, and a value equal to 1 indicates perfect 
discrimination. The D-statistic quantifies the observed sepa-
ration between subjects with low and high predicted risks 
as predicted by the model and can be interpreted as the log 
hazard ratio for having SCD between the low- and high-risk 
groups of patients. A model with no discriminatory ability has 
a value of 0 for the D-statistic, with increasing values indicat-
ing greater separation.
Sensitivity Analysis: Septal Reduction 
Therapy
Patients with drug-refractory symptoms secondary to outflow 
tract obstruction frequently undergo septal reduction therapy 
after baseline assessment, which can potentially decrease SCD 
risk predictions by relieving LVOTgmax and reducing MWT.
3 To 
assess the impact of septal reduction therapy on the predic-
tive performance of the model, HCM Risk-SCD was validated 
without patients undergoing septal reduction therapy within 
5 years of follow-up.
Complete Case Analysis: HCM Risk-SCD 
and SCD End Points at 5 Years
The incidence of the SCD end point is reported in patients 
with all the data required to calculate the 5-year SCD risk. 
SCD end points are examined in 3 categories (<4%, 4% to 
<6%, ≥6%) based on the calculated 5-year SCD risk and the 
2014 ESC guideline recommendations. The clinical implica-
tions of ICD implantation with a threshold of ≥4%, ≥5%, and 
≥6% were examined by descriptive statistics.
RESULTS
Clinical Characteristics of the Cohort
The study enrolled a total of 3902 patients, including 
199 (5%) with extreme clinical characteristics. The vali-
dation cohort consisted of 3703 patients; the baseline 
clinical characteristics are shown in Table 1. The cohort 
was composed of 87 (2.4%) patients aged <20 years, 
278 (7.5%) aged 20 to <30 years, 529 (14.3%) aged 
30 to <40 years, 703 (19%) aged 40 to <50 years, 861 
(23.3%) aged 50 to <60 years, 806 (21.8%) aged 60 to 
<70 years, and 439 (11.9%) aged 70 to 80 years. One 
hundred fifty-one patients (4%) were diagnosed on the 
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basis of familial criteria.9 Data on self-reported ethnicity 
were available in 3177 (86%) patients; the cohort was 
composed of 2631 white (71%), 385 Asian (10%), and 
99 black (3%) patients, and 62 patients of mixed/other 
ethnicity (2%), with 14% missing data. During follow-
up, 397 (11%) patients received an ICD.
SCD End Points During Follow-Up
During a follow-up period of 28 186 patient-years (me-
dian, 5.9 [3.0, 10] years; range, 2 days [SCD end point] 
to 39.6 years [censored]), 159 patients (4%) reached 
the SCD end point with an annual rate of 0.6% (95% 
confidence interval [CI], 0.5–0.7). Appropriate ICD 
shocks contributed 42 SCD end points (26%). Seventy-
three (2%) patients reached the SCD end point within 
5 years of follow-up, with a 5-year incidence of 2.4% 
(95% CI, 1.9–3.0). Twenty SCD end points within 5 
years occurred in patients with a family history of SCD, 
but there was no familial clustering of end points (de-
fined as >2 SCDs in individuals from the same family 
group). The clinical characteristics of patients with and 
without the SCD end point are shown in Table 2.
Missing Data
Missing data were observed in 6 of the 7 HCM Risk-SCD 
predictor variables: nonsustained ventricular tachycar-
dia, 30%; LVOTgmax, 17%; unexplained syncope, 2%; 
family history of SCD, 2%; left atrial diameter, 10%; 
and MWT, 0.8%. Complete data for the calculation of 
HCM Risk-SCD estimates were available in 2147 (58%) 
patients. Missingness was associated with systolic blood 
pressure, alcohol septal ablation, myectomy, ethnicity, 
New York Heart Association III/IV, ICD, pacemaker, ami-
odarone atrial fibrillation, left ventricular end-diastolic 
pressure, center, and all-cause mortality.
Model Validation
Validation revealed a calibration slope of 1.02 (95% 
CI, 0.93–1.12). Figure 1 illustrates a good agreement 
between the observed and predicted risk of SCD at 5 
years, particularly in the low-risk groups. The C-index 
was 0.70 (95% CI, 0.68–0.72). The D-statistic was 1.17 
(95% CI, 1.05–1.29), suggesting that the hazard of 
SCD is 3.2 times higher in the high-risk group than in 
the low-risk group as predicted by the model.
Table 1. Baseline Clinical Characteristics
Baseline Clinical 
Characteristics Validation 
Cohort
Patients With 
Extreme 
Characteristics*
HCM Risk-SCD 
Development 
Cohort, EHJ 
2014
Number of patients 3703 199 3675
Male, n (%) 2241 (61) 89 (45) 2349 (64)
Age, y 52±15 70±19 48±17
NYHA III/IV, n (%) 660 (19) 63 (32) 426 (12)
Prior myectomy, n (%) 77 (2) 5 (3) 34 (1)
Prior alcohol septal 
ablation, n (%)
23 (0.6) 0 10 (0.3)
Amiodarone, n (%) 297 (8) 17 (9) 468 (13)
ICD, n (%) 123 (3) 7 (4) 42 (1)
Permanent/persistent 
AF, n (%)
433 (12) 34 (17) 366 (10)
NSVT, n (%) 582 (22) 39 (31) 634 (17)
LA diameter; mm 43±8 49±12 44±8
LVOTgmax, mm Hg 11 (7, 55) 36 (9, 100) 12 (5, 49)
LVedd, mm 45±7 44±7 45±7
MWT, mm 20±4 23±8 20±5
FS, % 42±10 43±11 41±9
FHSCD, n (%) 620 (17) 19 (10) 886 (24)
Unexplained syncope, 
n (%)
474 (13) 31 (16) 507 (14)
Values are mean±SD, median (25th, 75th percentiles).
AF indicates atrial fibrillation; EHJ, European Heart Journal; FHSCD, 
family history of sudden cardiac death; FS, fractional shortening; HCM, 
hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; LA, 
left atrium; LVedd, left ventricular end-diastolic dimension; LVOTgmax, maximal 
instantaneous left ventricular outflow tract gradient at rest or Valsalva; MWT, 
maximal wall thickness; NSVT, nonsustained ventricular tachycardia; NYHA, 
New York Heart Association; and SCD, sudden cardiac death.
*HCM Risk-SCD is currently not recommended in patients underrepresented 
in the development cohort (left atrial diameter >67 mm, left ventricular outflow 
tract gradient >154 mm Hg, maximal wall thickness >35 mm, or age >80 y).
Table 2. Baseline Clinical Characteristics of Patients 
With and Without the SCD End Point at 5 Years of 
Follow-Up
Baseline Clinical Characteristic
Patients 
Without SCD 
End Points
n=3630 (98%)
Patients With 
SCD End Points 
Within 5 y
n=73 (2%)
Male, n (%) 2196 (61) 45 (62)
Age, y 52±15 46±15
NYHA III/IV, n (%) 647 (19) 13 (18)
Myectomy, n (%) 76 (2) 1 (1)
Alcohol septal ablation, n (%) 21 (0.6) 2 (3)
Amiodarone, n (%) 279 (8) 18 (25)
Permanent/persistent AF, n (%) 415 (12) 18 (25)
NSVT, n (%) 558 (22) 24 (44)
LA diameter, mm 43±8 44±7
LVOTgmax, mm Hg 12 (7, 55) 11 (9, 73)
LVedd, mm 45±7 46±7
MWT, mm 20±4 22±5
FS, % 42±10 43±12
FHSCD, n (%) 600 (17) 20 (27)
Unexplained syncope, n (%) 457 (13) 17 (23)
Values are mean±SD, median (25th, 75th percentiles). 
AF indicates atrial fibrillation; FHSCD, family history of sudden cardiac death; 
FS, fractional shortening; LA, left atrium; LVedd, left ventricular end diastolic 
dimension; LVOTgmax, maximal instantaneous left ventricular outflow tract 
gradient at rest or Valsalva; MWT, maximal wall thickness; NSVT, nonsustained 
ventricular tachycardia; NYHA, New York Heart Association; and SCD, sudden 
cardiac death.
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Sensitivity Analysis: Septal Reduction 
Therapy
A total of 670 (18%) patients had septal reduction 
therapy during their clinical course (542 myectomies 
and 150 alcohol septal ablations, with 22 patients hav-
ing both procedures). Their baseline clinical character-
istics are shown in Table 3. Of the 518 patients who 
had septal reduction therapy within 5 years of their first 
evaluation, 85% were low- or intermediate-risk and 8 
(1.5%) reached the SCD end point within that period. 
The calibration slope for the model after excluding pa-
tients with septal reduction therapy within 5 years of 
baseline evaluation was 1.09 (95% CI, 0.99–1.18), the 
C-index was 0.71 (95% CI, 0.68–0.73), and the D-sta-
tistic was 1.17 (95% CI, 1.0–1.25).
Complete Case Analysis: HCM Risk-SCD 
and SCD End Points at 5 Years
The 2147 (58%) patients with complete data had a 
median 5-year risk of SCD of 2.6% (1.7, 4.4). During a 
follow-up period of 14 496 years (median, 5.4 [2.8, 8.5] 
years), a total of 96 SCD end points were observed, and 
44 patients reached the SCD end point within 5 years (Ta-
ble 4, Figures 2 and 3). Patients not reaching the SCD end 
point at 5 years (n=2103) had a median predicted 5-year 
SCD risk of 2.6% (1.7%, 4.3%), whereas the correspond-
ing calculated risk for those reaching the SCD end point 
(n=44) was 6.2% (3.2%, 8.6%). The majority (28/44; 
64%) of SCD end points within 5 years of baseline evalu-
ation occurred in patients with a 5-year risk of ≥4% (high- 
and intermediate-risk groups), and although only 14% 
of patients had a HCM-Risk SCD ≥6% (high-risk group), 
these patients contributed 52% of SCD end points. Inter-
mediate-risk patients formed 15% of the cohort (n=326) 
and included 195 patients with a calculated risk of 4.0% 
to 4.99% with 1 (0.5%) SCD end point within 5 years of 
baseline evaluation. In the remaining 131 intermediate-
risk patients who had a predicted risk of 5.0% to 5.99%, 
4 (3%) had a SCD end point within 5 years.
Of the 623 patients with ≥4% SCD risk at 5 years, 
28 experienced a SCD end point, which suggests that 
for every 22 (623/28) ICD implantations in this group, 1 
patient can potentially be saved from SCD in that time 
period. Of the 428 patients with ≥5% SCD risk at 5 
years, 27 experienced a SCD end point, which suggests 
that for every 16 (428/27) ICD implantations, 1 patient 
can potentially be saved from SCD at 5 years. Of the 
297 patients with ≥6% SCD risk at 5 years, 23 expe-
rienced a SCD end point, suggesting that for every 13 
(297/23) ICD implantations in this group of patients, 1 
patient can potentially be saved from SCD at 5 years. 
Of the 1524 patients with <4% SCD risk at 5 years, 16 
experienced a SCD end point, suggesting that for every 
Figure 1. Calibration by risk group. 
Circles represent observed (obs) and diamonds represent pre-
dicted (pred) probabilities of SCD in 5 years using a random 
multiple imputation data set. The 4 risk groups (1–4) were 
created using model-based predicted probabilities (0%–2%, 
2%–4%, 4%–6%, and >6% 5-year risk of SCD). These 
groups are selected for the purposes of validation rather than 
clinical decision making. SCD indicates sudden cardiac death.
Table 3. Baseline Clinical Characteristics of Patients 
With and Without Septal Reduction
Baseline Clinical 
Characteristics
Patients 
Without 
Septal 
Reduction 
Therapy 
(n=3033)
Patients 
With Septal 
Reduction 
Therapy 
Before First 
Evaluation 
(n=98)
Patients 
With Septal 
Reduction 
Therapy During 
Follow-Up 
(n=572)
Time interval between 
septal reduction and 
baseline evaluation, y
NA 2.2 (0.4, 8.0) 0.11 (0.01, 1.3)
Male, n (%) 1883 (62) 44 (45) 314 (55)
Age, y 52±15 52±15 51±14
NYHA III/IV, n (%) 319 (11) 27 (26) 315 (55)
Amiodarone, n (%) 216 (7) 21 (22) 60 (10)
Permanent/persistent 
AF, n (%)
380 (13) 19 (21) 34 (6)
NSVT, n (%) 494 (22) 21 (37) 67 (22)
LA diameter, mm 43±8 47±9 47±8
LVOTgmax, mm Hg 8 (6, 35) 17 (8, 72) 64 (29, 100)
LVedd, mm 45±7 45±7 43±7
MWT, mm 19±4 19±5 21±4
FS, % 41±10 40±13 45±9
FHSCD, n (%) 508 (17) 18 (19) 94 (17)
Unexplained syncope, 
n (%)
364 (12) 12 (13) 98 (18)
Values are mean±SD, median (25th, 75th percentiles).
AF indicates atrial fibrillation; FHSCD, family history of sudden cardiac death; 
FS, fractional shortening; LA, left atrium; LVedd, left ventricular end diastolic 
dimension; LVOTgmax, left ventricular outflow tract gradient at rest or Valsalva; 
MWT, maximal wall thickness; NA, not available; NSVT, nonsustained ventricular 
tachycardia; and NYHA, New York Heart Association.
D
ow
nloaded from
 http://ahajournals.org by on October 30, 2018
O’Mahony et al Sudden Death in Hypertrophic Cardiomyopathy
March 6, 2018 Circulation. 2018;137:1015–1023. DOI: 10.1161/CIRCULATIONAHA.117.0304371020
OR
IG
IN
AL
 R
ES
EA
RC
H 
AR
TI
CL
E
95 (1524/16) patients not implanted an ICD, 1 can po-
tentially die suddenly within 5 years.
SCD End Points in Patients With Extreme 
Clinical Characteristics
A group of 199 patients (199/3902; 5%) had extreme 
clinical characteristics, including 111 patients aged >80 
years, 31 patients with LVOTgmax >154 mm Hg, 28 pa-
tients with left atrial diameter >67 mm, and 34 patients 
with MWT>35 mm (5 patients had >1 outlying clini-
cal characteristic). The baseline clinical characteristics of 
these patients are shown in Table 1.
During a follow-up period of 1102 patient-years (me-
dian, 4.5 [2.1, 7.5] years; range, 6 days [SCD end point] 
to 24.0 years [censored]), 16 patients (8%) reached the 
SCD end point. Nine (4%) patients reached the SCD 
end point within 5 years of baseline assessment. The 
annual rate of SCD end point was 1.5% (95% CI, 0.9–
2.4) with a 5-year cumulative incidence of 5.9% (95% 
CI, 3.0–11.1). Appropriate ICD shocks did not contrib-
ute to SCD end points. Seven (7/16; 44%) SCD end 
points occurred in patients aged >80 years.
DISCUSSION
This study demonstrates that HCM Risk-SCD provides 
accurate SCD risk estimates in patients recruited in mul-
tiple different localities around the world and illustrates 
the positive impact of the 2014 ESC recommendations 
on clinical decision making. Specifically, it shows that 
the risk-benefit ratio for ICD implantation is most fa-
vorable in individuals with an estimated 5-year risk of 
≥6%.
The clinical usefulness of the 2014 ESC guidelines for 
sudden death prevention is dependent on the perfor-
mance of the HCM Risk-SCD tool, and external valida-
tion studies are essential to demonstrate the accuracy 
of its predictions in diverse patient populations. HCM 
Risk-SCD performance was similar to that reported in the 
original study and is consistent with several smaller exter-
nal validation cohorts from Europe and South America.4–6 
An exception is a study of patients from 2 North Ameri-
can centers in which HCM Risk-SCD had a high negative 
predictive value but was less reliable in predicting long-
term outcomes.7 However, direct comparison with the 
present analysis is difficult, because the North American 
study did not report discrimination, calibration, or end 
points within 5 years of baseline evaluation.7
This study shows that HCM Risk-SCD can be used 
to avoid unnecessary ICD implants in low-risk patients. 
The large majority of HCM patients had a 5-year risk of 
SCD of <4%, and the very low SCD end point rate in 
this patient subgroup, reported in this and other stud-
ies,4,5,7 supports the 2014 ESC recommendation not 
to implant an ICD in individuals with a low estimated 
risk.2 Conversely, patients with a predicted 5-year risk 
of SCD ≥6% formed a small subgroup that had the 
highest event rate and the largest absolute number of 
events.2 In patients with a high estimated 5-year risk, 
Table 4. Events in Patients With Complete Data Set to Calculate HCM Risk-SCD
Calculated HCM Risk-SCD at 5 y in 2147 Patients: Risk Category
<4% 4% to <6% ≥6%
2014 ESC guideline recommendation on ICD 
implantation
Not recommended if there are no 
other clinical features that are of 
proven prognostic importance (III, B)
May be considered in 
individual patients (IIb, B)
Should be considered (IIa, B)
Patients, n (%) 1524 (71) 326 (15) 297 (14)
SCD end points within 5 y, n (%) 16 (1) 5* (1.5) 23 (7)
5-y incidence of SCD 1.4% (95% CI, 0.8–2.2) 1.8% (95% CI, 0.7–4.3) 8.9% (95% CI, 5.96–13.1)
Annual rate of SCD end point within 5 y of evaluation 0.27% (95% CI, 0.17–0.44) 0.39% (95% CI, 0.16–0.93) 1.92% (95% CI, 1.27–2.88)
CI indicates confidence interval; ESC, European Society of Cardiology; HCM, hypertrophic cardiomyopathy; and SCD, sudden cardiac death.
*Four of 5 patients had a predicted 5-year SCD risk >5%; in total, 428 patients had 5-year risk ≥5% with 27 SCD end points.
Figure 2. Kaplan-Meier curve showing SCD end points 
within 5 years of baseline evaluation, stratified accord-
ing to the estimated 5-year risk of SCD. 
Patients with complete data for the calculation of HCM 
Risk-SCD estimates (n=2147) were classified in 3 risk groups 
in accordance to the 2014 ESC guidelines (HCM Risk-SCD 
<4%, 4% to <6%, ≥6%). The at-risk table shows the 
number of SCD end points in parentheses. ESC indicates 
European Society of Cardiology; HCM, hypertrophic cardio-
myopathy; and SCD, sudden cardiac death.
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the predicted event rates were slightly overestimated, 
but this is less of a problem in clinical practice because 
this group of patients still had the highest event rate 
(≥6% at 5 years) and, as a result, have the greatest ben-
efit from prophylactic ICD therapy.
Because there is no consensus on the absolute SCD 
risk that justifies ICD therapy, there are some patients 
in whom clinical decision making is more complex and 
determined by more than a simple estimation of SCD 
risk. This is reflected in the 2014 ESC guidelines in the 
form of an intermediate-risk category (5-year risk of 
≥4% to <6%) in which an ICD may be considered fol-
lowing a detailed clinical assessment and an appraisal 
of the lifelong risks and benefits of device therapy. This 
study suggests that most intermediate-risk patients can 
be managed conservatively, but ICDs have the potential 
to prevent some sudden deaths in this subgroup, espe-
cially in those with a 5-year risk of ≥5%. The downside 
of using a lower-risk threshold for ICD implantation is 
the greater healthcare cost and unnecessary exposure 
of more individual patients to the long-term complica-
tions of devices.
Because patients with HCM are generally young, it 
is reasonable to conjecture that some will change their 
risk profile during follow-up, thereby violating one of 
the model’s basic assumptions. To account for this, the 
2014 ESC guidelines recommend that patients seek 
medical attention if their clinical condition changes and 
that patients should be routinely reassessed every 12 
to 24 months.2 Although it will be challenging, future 
iterations of the HCM Risk-SCD model may be able to 
test its performance beyond 5 years if a sufficient num-
ber events are observed.
Patients with extreme values for individual risk fac-
tors were underrepresented in the original HCM Risk-
SCD development cohort,3 and consequently, the 2014 
ESC guidelines do not recommend the use of the model 
in such patients.2 Patients with extreme clinical char-
acteristics were also uncommon in this study, which 
implies that the 2014 ESC guidelines are applicable to 
most patients seen in clinical practice. Furthermore, 
most were >80 years of age, a group in whom ICD 
implantation is frequently inappropriate because of co-
morbid conditions.
Patients undergoing septal reduction therapy were 
more frequent in this study (18%) than in the devel-
opment cohort (9%).3 Even though septal reduction 
therapy may have an impact on disease outcomes, the 
sensitivity analysis in this study suggests that the ac-
curacy of HCM Risk-SCD predictions is not significantly 
affected by septal reduction therapy in the short term. 
These data suggest that SCD risk stratification should 
be undertaken independently but in parallel with the 
management of symptomatic left ventricular outflow 
tract obstruction. The small number of SCD end points 
in this subgroup does not allow an examination of the 
prognostic impact of septal reduction or a direct com-
parison of SCD rates following myectomy and alcohol 
septal ablation.
As with other widely used clinical risk tools, it is es-
sential that HCM Risk-SCD and the 2014 ESC guidelines 
continue to be the subject of constant reassessment in 
diverse patient populations to ensure accuracy in varied 
clinical scenarios. Risk stratification can potentially be 
improved by examining the incremental predictive value 
of other patient characteristics such as genotype and 
myocardial scar burden in future studies.24,25 Despite 
the promise of future improvements, there will always 
be inherent uncertainty exemplified by sudden deaths 
in apparently low-risk patients and lack of events in 
high-risk patients with past and present risk stratifica-
tion strategies.26,27 No risk stratification strategy will 
ever be able to predict all sudden deaths, but quan-
tification of risk enhances the shared decision-making 
process and may aid the development of an effective 
decision-making tool in the future.28
This study has a number of limitations. A retrospec-
tive, multicenter design was essential, because the low 
SCD rate makes prospective validation studies challeng-
ing because a large number of patients needs to be 
followed up for prolonged time periods. Despite the 
size of the study cohort, there were only 74 SCD end 
points within 5 years. However, the narrow 95% CIs of 
Figure 3. The annual rate of SCD end points within 5 
years of baseline evaluation stratified according the 
estimated 5-year risk of SCD. 
The annual risk of SCD end points and the 95% confidence 
intervals for the three 2014 ESC guidelines risk groups (HCM 
Risk-SCD <4%, 4% to <6%, ≥6%) are shown (complete 
case analysis n=2147). ESC indicates European Society of 
Cardiology; HCM, hypertrophic cardiomyopathy; and SCD, 
sudden cardiac death.
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the validation measures suggest that these have been 
estimated with reasonable precision. This validation 
study had more missing data than the original develop-
ment study, but appropriate statistical techniques were 
used to correct for this. Patients aged 16 to 20 years 
were relatively underrepresented, and the validity of the 
model in this population may require further study.
This external validation study shows that the HCM 
Risk-SCD model and 2014 ESC guidelines provide ac-
curate prognostic information in patients with HCM 
that can be used to identify patients with a high risk of 
potentially fatal ventricular arrhythmia in the short to 
medium term. Although no risk stratification strategy 
can predict all events, quantification of risk enhances 
the shared decision-making process and provides the 
basis for consistent and effective treatment choices.
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